Vnitr Lek 2026, 72(3):148-150 | DOI: 10.36290/vnl.2026.032

Advances in asthma treatment

Tomáš Slisz
Oddělení alergologie a klinické imunologie Gennet, Pneumologická klinika 1. LF UK a FTN v Praze

This review summarizes the latest GINA 2025 recommendations, focusing on updated diagnostic criteria, particularly in pediatric patients, the role of biomarkers such as FeNO and blood eosinophils, and modern therapeutic strategies. Special emphasis is placed on the anti-inflammatory reliever concept, which promotes the use of low-dose ICS-formoterol as needed across all severity steps. The article also reviews recent developments in biologic therapy, including expanded indications for dupilumab, the use of tezepelumab across asthma phenotypes, and the emerging role of long-acting agents such as depemokimab. Environmental factors influencing disease control and the importance of sustainability in inhaler therapy are also discussed. The aim of this article is to provide a practical overview of current trends and their implementation in clinical practice to improve asthma control and reduce the risk of exacerbations.

Keywords: bronchial asthma, GINA 2025, biomarkers, FeNO, biologic therapy, depemokimab, tezepelumab, dupilumab.

Accepted: April 23, 2026; Published: May 18, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slisz T. Advances in asthma treatment. Vnitr Lek. 2026;72(3):148-150. doi: 10.36290/vnl.2026.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2025 Report) [Internet]. GINA; 2025 [cited 2026-03-26]. Available from: https://ginasthma.org/2025-gina-strategy-report/.
    2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2024 GINA Main Report) [Internet]. GINA; 2024 [cited 2026-03-26]. Available from: https://ginasthma.org/2024-report/.
    3. Ducharme FM, Chan R. Oscillometry in the diagnosis, assessment, and monitoring of asthma in children and adults. Ann Allergy Asthma Immunol. 2025;134:135-143. Go to original source... Go to PubMed...
    4. Högman M, Bowerman C, Chavez L, et al. ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (FENO50). Eur Respir J. 2024;63(1):2300370. Go to original source... Go to PubMed...
    5. Meulmeester FL, Mailhot-Larouche S, Celis-Preciado C, et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025; Online ahead of print. doi:10.1016/S2213-2600(25)00037-2. Go to original source... Go to PubMed...
    6. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. doi: 10.1056/NEJMoa2034975. Go to original source... Go to PubMed...
    7. Hatter L, Holliday M, Eathorne A, et al. The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis. Eur Respir J. 2024;64:2301705. Go to original source... Go to PubMed...
    8. Busby J, Holmes J, Almutairi M, et al. Exploring the Long-Term Utility of Remotely Monitored FeNO Suppression Testing in Severe Asthma. J Allergy Clin Immunol Pract. 2025;13(7):1816-1823. doi: 10.1016/j.jaip.2025. 04. 036. Go to original source...
    9. Dupilumab (Dupixent). Summary of Product Characteristics [Internet]. European Medicines Agency; 2024 [cited 2026-03-26]. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf.
    10. Weinstein SF, FitzGerald JM, Humbert M, et al. Depemokimab in patients with severe eosinophilic asthma. N Engl J Med. 2024;390(4):321-333. doi:10.1056/NEJMoa2308425. Go to original source...
    11. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of depemokimab in severe eosinophilic asthma: results from a phase 3 randomized controlled trial. Lancet Respir Med. 2025;13(1):45-57. doi: 10.1016/S2213-2600(24)00312-8. Go to original source...
    12. Pavord ID, Chanez P, Bleecker ER, et al. Anti-IL-5 therapies for severe eosinophilic asthma: current status and future perspectives including long-acting agents. Eur Respir J. 2024;63(2):2301589. doi: 10.1183/13993003.01589-2023. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.